Tranexamic Acid and Bevacizumab in Hereditary Hemorrhagic Telangiectasia Patients Presenting With Epistaxis

被引：0
|
作者：
Lacout, Alexis [1 ]
Marcy, Pierre-Yves [2 ]
El Hajjam, Mostafa [3 ]
Lacombe, Pascal [3 ]
机构：
[1] Ctr Imagerie Med, Aurillac, France
[2] Francois Baclesse Canc Res Inst, Radiodiagnost Dept, Caen, France
[3] Hop Ambroise Pare, AP HP, Serv Radiol, Boulogne Billancourt, France
来源：
CUTIS | 2013年 / 91卷 / 04期
关键词：
MUTATION; HHT;
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：173 / 174
页数：2
相关论文
共 50 条
  • [41] Epistaxis in patients with hereditary hemorrhagic telangiectasia treated with selective arterial embolization
    Trojanowski, Piotr
    Jargiello, Tomasz
    Trojanowska, Agnieszka
    Klatka, Janusz
    ACTA RADIOLOGICA, 2011, 52 (08) : 846 - 849
  • [42] An evaluation of the severity and progression of epistaxis in hereditary hemorrhagic telangiectasia 1 versus hereditary hemorrhagic telangiectasia 2
    Hunter, Benjamin N.
    Timmins, Benjamin H.
    McDonald, Jamie
    Whitehead, Kevin J.
    Ward, P. Daniel
    Wilson, Kevin F.
    LARYNGOSCOPE, 2016, 126 (04): : 786 - 790
  • [43] Effect of bevacizumab nasal spray on epistaxis duration in hereditary hemorrhagic telangiectasia: a randomized clinical trial
    Dupuis-Girod, S.
    Ambrun, A.
    Decullier, E.
    Fargeton, A. E.
    Roux, A.
    Broant, V
    Colombet, B.
    Riviore, S.
    Cartier, C.
    Lacombe, P.
    Chinet, T.
    Blivet, S.
    Blondel, J. H.
    Gilbert-Dussardier, B.
    Dufour, X.
    Michel, J.
    Harle, J. R.
    Dessi, P.
    Faure, F.
    ANGIOGENESIS, 2018, 21 (01) : 118 - 118
  • [44] Bevacizumab: an option for refractory epistaxis in hereditary haemorrhagic telangiectasia
    Arno Amann
    Normann Steiner
    Eberhard Gunsilius
    Wiener klinische Wochenschrift, 2015, 127 : 631 - 634
  • [45] Bevacizumab: an option for refractory epistaxis in hereditary haemorrhagic telangiectasia
    Amann, Arno
    Steiner, Normann
    Gunsilius, Eberhard
    WIENER KLINISCHE WOCHENSCHRIFT, 2015, 127 (15-16) : 631 - 634
  • [46] Bevacizumab for the treatment of liver involvement in patients with hereditary hemorrhagic telangiectasia
    Issachar, Assaf
    Cohen-Naftaly, Michal
    Arbib, Orly Sneh
    Tur-Kaspa, Ran
    Shlomai, Amir
    Braun, Marius
    Mei-Zahav, Meir
    JOURNAL OF HEPATOLOGY, 2019, 70 (01) : E584 - E585
  • [47] Systemic therapy with bevacizumab in patients with hereditary hemorrhagic telangiectasia (HHT)
    Chavan, Ajay
    Schumann-Binarsch, Silke
    Luthe, Lars
    Nickau, Britta
    Elsaesser, Albrecht
    Kuehnel, Thomas
    Geisthoff, Urban
    Koehne, Henning
    VASA-EUROPEAN JOURNAL OF VASCULAR MEDICINE, 2013, 42 (02) : 106 - 110
  • [48] SURGICAL-MANAGEMENT OF EPISTAXIS IN HEREDITARY HEMORRHAGIC TELANGIECTASIA
    ZOHAR, Y
    SADOV, R
    SHVILI, Y
    TALMI, Y
    LAURIAN, N
    ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY, 1987, 113 (07) : 754 - 757
  • [49] Intranasal Efudix reduces epistaxis in hereditary hemorrhagic telangiectasia
    de Jel, D. V. C.
    Disch, F. J. M.
    Kroon, S.
    Mager, J. J.
    Verdam, F. J.
    ANGIOGENESIS, 2020, 23 (03) : 271 - 274
  • [50] HEREDITARY HEMORRHAGIC TELANGIECTASIA - YOUNG PROCEDURE IN THE MANAGEMENT OF EPISTAXIS
    HOSNI, AA
    INNES, AJ
    JOURNAL OF LARYNGOLOGY AND OTOLOGY, 1994, 108 (09): : 754 - 757
12345